PFIZER INC Derivative Asset, Current
PFIZER INC (PFE) had Derivative Asset, Current of $471.00 million as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DerivativeAssetsCurrent · last filed 2026-08-04
- 2026-06-28: Derivative Asset, Current $471.00M.
- 2026-03-29: Derivative Asset, Current $504.00M.
- 2025-12-31: Derivative Asset, Current $416.00M.
- 2024-12-31: Derivative Asset, Current $1.06B.
| Period end | Derivative Asset, Current |
|---|---|
| 2026-06-28 | $471.00M 10-Q · filed 2026-08-04 |
| 2026-03-29 | $504.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $416.00M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $1.06B 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |